The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of our users, ...

DexCom Inc. DXCM recently announced the direct connectivity of the Dexcom G7 Continuous Glucose Monitoring (CGM) system with the Apple Watch. This added feature is now available to users in the United ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Dexcom has won a nod from FDA for the G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. With this clearance, the San Diego, CA-based company continues to ...

A new clinical trial to investigate the use of artificial pancreas system is set to begin, bringing in touchscreen insulin pump maker Tandem Diabetes Care; Dexcom, which makes continuous glucose ...

Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch. Dexcom G7 15 Day is expected to launch ...